Sutro Biopharma (STRO) closed at $9.62 on November 6, 2026, up 4.6% from the previous close, on volume of 176,093 shares (30-day average 308,432).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Call Spread | 21-May-2710 : 20 C | 216 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
3 ‘Strong Buy’ High-Risk Stocks That Could Offer Mouthwatering Returns
TipRanks (Wed, 4-Nov 2:57 PM ET)
3 ‘Strong Buy’ High-Risk Stocks That Could Offer Mouth-Watering Returns
TipRanks (Wed, 4-Nov 2:57 PM ET)
Sutro Biopharma to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Globe Newswire (Wed, 21-Oct 8:00 AM ET)
Market Chameleon (Mon, 12-Oct 7:53 AM ET)
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Globe Newswire (Mon, 12-Oct 8:00 AM ET)
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Wed, 12-Aug 7:00 AM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of November 6, 2026, STRO stock price climbed to $9.62 with 176,093 million shares trading.
STRO has a beta of 2.13, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.08 to the broad based SPY ETF.
STRO has a market cap of $159.38 million. This is considered a Micro Cap stock.
Last quarter Sutro Biopharma reported $10 million in Revenue and -$2.33 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.11.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, IWM, VXF, FESM, VTWO.
STRO has underperformed the market in the last year with a return of +2.1%, while the SPY ETF gained +10.8%. In the last 3 month period, STRO fell short of the market, returning -60.2%, while SPY returned -4.1%. However, in the most recent 2 weeks STRO has outperformed the stock market by returning +3.1%, while SPY returned -3.2%.
STRO support price is $8.58 and resistance is $9.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.